Alnylam Pharmace. buy Canaccord Genuity Group Inc.
Start price
17.02.26
/
50%
€281.10
Target price
17.02.27
€362.20
Performance (%)
-2.35%
Price
13.03.26
€274.50
Summary
This prediction is currently active. With a performance of -2.35%, the BUY prediction for Alnylam Pharmace. by Canaccord_Genuity_Gr is down slightly. This prediction currently runs until 17.02.27. The prediction end date can be changed by Canaccord_Genuity_Gr at any time. Canaccord_Genuity_Gr has 50% into this predictionAlnylam Pharmaceuticals, Inc. (ALNY) is a biopharmaceutical company focused on the development of RNA interference (RNAi) therapeutics. Its lead drug, ONPATTRO®, is approved by the U.S. FDA for the treatment of adults with polyneuropathy of hereditary transthyretin-mediated (hATTR) amyloidosis. The company is also developing additional RNAi therapeutic candidates for the treatment of a range of diseases, including cancer, cardiovascular disease, and viral infections. With a market capitalization of over $15 billion, Alnylam is one of the largest biotech companies in the world.
Performance without dividends (%)
| Name | 1w |
|---|---|
| Alnylam Pharmace. | -0.651% |
| iShares Core DAX® | -1,10 % |
| iShares Nasdaq 100 | 0,33 % |
| iShares Nikkei 225® | -1,08 % |
| iShares S&P 500 | -0,06 % |
Comments by Canaccord_Genuity_Gr for this prediction
In the thread Alnylam Pharmace. diskutieren
Alnylam Pharmaceuticals (NASDAQ:ALNY) had its price target raised by analysts at Canaccord Genuity Group Inc. from $415.00 to $429.00. They now have a "buy" rating on the stock.
Ratings data for ALNY provided by MarketBeat